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ABSTRACT Rapid and accurate drug susceptibility testing (DST) is essential for
the treatment of multi- and extensively drug-resistant tuberculosis (M/XDR-TB).
We compared the utility of genotypic DST assays with phenotypic DST (pDST)
using Bactec 960 MGIT or Löwenstein-Jensen to construct M/XDR-TB treatment
regimens for a cohort of 25 consecutive M/XDR-TB patients and 15 possible
anti-TB drugs. Genotypic DST results from Cepheid GeneXpert MTB/RIF (Xpert)
and line probe assays (LPAs; Hain GenoType MTBDRplus 2.0 and MTBDRsl 2.0)
and whole-genome sequencing (WGS) were translated into individual algorithm-
derived treatment regimens for each patient. We further analyzed if discrepan-
cies between the various methods were due to ﬂaws in the genotypic or pheno-
typic test using MIC results. Compared with pDST, the average agreement in the
number of drugs prescribed in genotypic regimens ranged from just 49% (95%
conﬁdence interval [CI], 39 to 59%) for Xpert and 63% (95% CI, 56 to 70%) for
LPAs to 93% (95% CI, 88 to 98%) for WGS. Only the WGS regimens did not con-
tain any drugs to which pDST showed resistance. Importantly, MIC testing re-
vealed that pDST likely underestimated the true rate of resistance for key drugs
(rifampin, levoﬂoxacin, moxiﬂoxacin, and kanamycin) because critical concentra-
tions (CCs) were too high. WGS can be used to rule in resistance even in M/XDR
strains with complex resistance patterns, but pDST for some drugs is still needed
to conﬁrm susceptibility and construct the ﬁnal regimens. Some CCs for pDST
need to be reexamined to avoid systematic false-susceptible results in low-level
resistant isolates.
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Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide (1).Although the global incidence of TB has been slowly declining, the emergence of
multidrug-resistant TB (MDR-TB), deﬁned as resistance to rifampin and isoniazid, chal-
lenges TB control (1). Extensively drug-resistant TB (XDR-TB), deﬁned as MDR-TB and
resistance to at least one ﬂuoroquinolone (e.g., oﬂoxacin, levoﬂoxacin, or moxiﬂoxacin;
World Health Organization [WHO] group A) and any second-line injectable drug (SLID;
amikacin, kanamycin, or capreomycin; WHO group B) has been reported in 117 coun-
tries (1).
Therapy of M/XDR-TB is complex and requires a long duration of treatment with a
combination of at least four drugs, often leading to adverse events and poor treatment
outcomes (2, 3). Moreover, the initiation of appropriate therapy is often delayed due to
the low growth rate of Mycobacterium tuberculosis complex isolates, which means that
phenotypic drug susceptibility testing (pDST) can take weeks to months (4, 5). To
accelerate this rate-limiting step, a number of genotypic DST assays that detect
resistance mutations have been endorsed by the WHO (6). The Cepheid GeneXpert
(Xpert) is an automated point-of-care assay with a high diagnostic accuracy for
rifampin resistance detection, providing results within 1.5 h (7). Line probe assays
(LPAs; e.g., Hain GenoType MTBDRplus 2.0 and MTBDRsl 2.0) also can be performed
directly from sputum to provide results within 1 to 2 days with a high diagnostic
accuracy for resistance to isoniazid, rifampin, ﬂuoroquinolones, and SLIDs (6).
Because these assays only target a limited number of resistance variants, their
sensitivity compared with that of pDST is limited. Whole-genome sequencing (WGS)
theoretically can overcome this shortcoming by interrogating the entire genetic
repertoire (4, 5, 8). Nevertheless, the utility of WGS is currently limited by the need
for expensive equipment, highly trained personnel, and complex bioinformatic
procedures. Moreover, WGS requires an initial culture, which introduces a delay
compared with the aforementioned targeted assays (6, 9). More fundamentally,
there is a lack of understanding of the genetic basis of antibiotic resistance, which
complicates the interpretation of WGS data (10).
However, it is important to appreciate that discrepancies observed between pDST
and genotypic methods are not exclusively due to problems related to the interpreta-
tion of the genotype (6). Instead, evidence is mounting that some critical concentra-
tions (CCs), which are set by the Clinical and Laboratory Standards Institute (CLSI)
and/or WHO and deﬁne resistance on a phenotypic level, are higher than the epide-
miological cutoff values (ECOFFs), which represent the highest concentration of the
wild-type MIC distribution (6, 11–15). As a result, some isolates with elevated MICs
compared to the ECOFF due to known mutations are classiﬁed as susceptible even
though limited pharmacokinetic/pharmacodynamics or clinical outcome data exist that
these isolates are still treatable (6, 12, 13, 16).
Therefore, this study had two main goals. First, we compared the utility of genotypic
methods (Xpert, LPAs, and WGS) with pDST to design M/XDR regimens using standard-
ized algorithms. Second, we analyzed whether discrepancies between the various
methods were due to ﬂaws in pDST or the genotype.
RESULTS
Patient cohort. Twenty patients with MDR-TB and 5 with XDR-TB admitted to the
Medical Clinic of the Research Center Borstel (Germany) were enrolled (see Table S1 in
the supplemental material).
Comparison of M/XDR-TB regimens based on pDST with molecular methods.
Three hundred sixty-seven pDST results for a total of 15 drugs served as the reference
standard (Fig. 1). Xpert classiﬁed all 25 patients as having rifampin resistance, yet one isolate
was phenotypically susceptible, resulting in an agreement of 96% (95% conﬁdence interval
[CI], 80 to 100%). LPA and pDST results agreed in 228 of 243 cases (94% [95% CI, 90 to
97%]). Three hundred forty of the 367WGS-based drug resistance predictions (93% [95% CI,
89 to 95%]) were concordant with pDST (Fig. 1A and Table S2).
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There was a 49% (95% CI, 39 to 59%) average agreement in the number of
antibiotics prescribed between the regimens based on Xpert results alone and those
based on pDST (Fig. 2 and Table S3) (3). This increased to 68% (95% CI, 56 to 80%) if
resistance to both ethambutol and pyrazinamide was also assumed based on the
discovery of rifampin resistance. Making the equivalent assumption for LPAs increased
the agreement from 63% (95% CI, 56 to 70%) to 87% (95% CI, 80 to 94%). The best
agreement with pDST regimens was achieved with WGS (93% [95% CI, 88 to 98%]) (Fig.
2 and Table S3). Importantly, the WGS regimens did not feature any drugs to which
resistance was found using pDST. In contrast, the 25 regimens that were designed using
LPAs or Xpert contained 56/152 (37% [95% CI, 29 to 56]) and 77/150 (51% [95% CI, 43
to 60%]) drugs, respectively, for which pDST showed resistance (Table S4).
A more detailed analysis of drug categories revealed that the Xpert regimens
involved an increased administration of group A, B, and D1 drugs compared with those
for pDST (P  0.001) (Table S5). Moreover, no D2 and D3 drugs were part of these
regimens (P  0.001). For the LPA regimens, only the increase in the number of D1
drugs was statistically signiﬁcant. In contrast, the use of WGS resulted in a signiﬁcant
decrease in the use of D1 drugs because more ethambutol resistance was predicted
(Table S5).
FIG 1 Comparison of pDST, Xpert, LPA, and WGS results and corresponding regimens. (Upper) Results for pDST and molecular methods (Xpert, LPAs, and WGS)
for 25 M. tuberculosis isolates from patients with M/XDR-TB. Test results denoting either conﬁrmed phenotypic susceptibility or assumed susceptibility based
on genotypic methods are shown in green, those denoting resistance are in red, gNWT variants with elevated MICs are in orange, and mutations with unclear
effects are in gray. Differences between Xpert, LPA, and WGS results compared to those of the pDST are outlined by black margins (both gNWT and unclear
variants were assumed to be resistant for the purposes of designing the regimens and results between DST methods). (Lower) Standard algorithm-derived
treatment regimens based on respective results of pDST, LPAs, WGS, and Xpert. Differences of resulting therapy regimens compared to the pDST-derived
treatments are highlighted by black boxes. Vertical bars indicate data for 15 drugs for each patient, i.e., from left to right, isoniazid (H), rifampin (R), rifabutin
(Rb), ethambutol (E), pyrazinamide (Z), kanamycin (Km), amikacin (Am), capreomycin (Cm), oﬂoxacin (Ox), moxiﬂoxacin (Mx), levoﬂoxacin (Lx), prothionamide
(Pt), para-aminosalicylic acid (Pa), cycloserine (Cs), terizidone (Tz), linezolid (Lz), amoxicillin-clavulanic acid (Ac), meropenem (Me), clofazimine (Cf), delamanid
(De), and bedaquiline (Bq).
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Analysis of the discrepancies between different DST methods. We determined
the MICs for selected isolates and antibiotics to investigate the potential causes of the
discrepancies observed with the different DST methods (Table S2).
Rifampin and rifabutin. One isolate (11102-14) with an rpoB D435Y mutation had
a MIC for rifampin that was below the CC but above the tentative ECOFF deﬁned in this
study (tentative ECOFF of 0.25 g/ml  rpoB mutant ECOFF of 0.5 g/ml  CC of 1
g/ml), which suggested that the susceptible pDST result represented a breakpoint
artifact (Fig. 3A). This isolate also tested susceptible to rifabutin at the CC of 0.5 g/ml
(Fig. 3B). In this case, however, the result was likely valid, as its MIC (0.06 g/ml) was
even lower than the tentative ECOFF (0.12 g/ml). In contrast, the susceptible pDST
results with rifabutin for the D435Y and L452P/E481A isolates (12041-13 and 999-13)
again were likely the result of breakpoint artifacts (17).
Isoniazid and prothionamide. All gWT isolates tested susceptible at the CLSI and
WHO CC of 0.1 g/ml. Conversely, all isolates with elevated MICs had known resistance
mutations. Although not endorsed by WHO and not considered for our hypothetical
regimens, CLSI has set 0.4 g/ml as an additional breakpoint to deﬁne low-level
resistance that can be treated with a high dose of isoniazid according to some
recommendations (Fig. 3C) (18). Based on our WGS results, we were able to predict that
all gNWT isolates were resistant even at this higher concentration (either because of the
katG S315T mutation, which is known to confer predominantly high-level resistance, or
because the isolates harbored both the inhA 15c/t promoter mutation and inhA
coding changes [S94A or I194T] [18, 19]). It was not possible to predict the correct level
of resistance for the inhA double mutants using MTBDRplus, given that this assay only
interrogates promoter mutations (20).
For prothionamide, we observed only a single disagreement between our WGS
predictions and those for pDST (21). Isolate 3758-14 originally tested susceptible
despite a frameshift mutation in ethA (22). However, this discrepancy was likely a
random error, since the isolate was found to have an elevated MIC compared with the
CC (25 g/ml versus 2.5 g/ml, respectively).
Levoﬂoxacin and moxiﬂoxacin. All seven isolates with known gyrA resistance
mutations were resistant to levoﬂoxacin at the CC of 1.5 g/ml (23). However, a review
FIG 2 Average overlap of different regimens based on molecular DST assays compared with pDST results.
Standard algorithm-derived treatment regimens based on results of Xpert, LPAs, and WGS (x axis) with
their mean overlap to standard algorithm-derived treatment regimens based on pDST results (y axis).
Mean overlaps (dots) are expressed with 95% conﬁdence intervals (bars). P values assessing the
differences between the mean overlaps between the treatment regimens are shown above.
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of MIC data from the literature revealed a tentative ECOFF of 0.75 g/ml, which resulted
in the misclassiﬁcation of 9 gyrA isolates from the literature (Fig. 4A).
WHO has set two CCs for moxiﬂoxacin. The lower CC, at 0.5 g/ml, is supposed to
correspond to the ECOFF and is intended as a surrogate for oﬂoxacin and levoﬂoxacin
resistance (14, 24). However, our pooled MIC data suggested that the tentative ECOFF
was actually 0.25 g/ml, which was in agreement with the current CLSI guidelines (Fig.
4B) (11). All of our gyrA mutants were resistant at 2 g/ml, the second WHO CC, which
should deﬁne resistance to moxiﬂoxacin itself (i.e., isolates with only slightly elevated
MICs of 1 and 2 g/ml are deemed to still be treatable with moxiﬂoxacin). However, in
light of the fact that WHO has already acknowledged that this CC may be too high and
given that predicting the precise MIC based on genotypic data alone is challenging, we
simply classiﬁed our isolates as gNWT (24).
SLIDs. The MIC distribution for isolates with known mutations in the resistance
genes eis and whiB7 ranged from 2.5 to 10 to 12.5 g/ml and was truncated by the
current CC of 2.5 g/ml, whereas all gWT isolates had MICs of 0.125 g/ml (25–27).
Therefore, the two isolates with a MIC of 2.5 g/ml (12471-13 and 11411-14) would
have tested resistant if the CC was lowered to the tentative ECOFF of 1.25 g/ml (Fig.
5A and Table S2). Moreover, we predict isolate 811-15, which had a known whiB7
resistance mutation (56 g/a), would retest resistant at 1.25 g/ml (it tested suscep-
FIG 3 MIC distributions for rifampin, rifabutin, and isoniazid. (A and B) The CCs for rifampin and rifabutin were two dilutions higher than the tentative ECOFFs
deﬁned based on the pooled MIC data from this study and the literature (i.e., 1 versus 0.25 g/ml for rifampin and 0.5 versus 0.12 g/ml for rifabutin) (17).
These distinctions did not make a difference for isolates with rpoB S450F or S450L mutations, which resulted in large MIC increases for both drugs. In contrast,
the result of susceptible/resistant to rifampin by pDST for the rpoB D435Y isolate (11102-14), as well as the rifabutin results for the rpoB D435V and L452P/E481A
isolates (12041-13 and 999-13), likely were breakpoint artifacts, as the isolates had elevated MICs compared to those of gWT isolates and the H37Rv laboratory
strain. In contrast, the rpoB D435Y isolate appeared to be genuinely susceptible to rifabutin. However, lowering the CCs for both drugs to the ECOFFs would
not necessarily ensure that isolates with elevated MICs always test resistant phenotypically. For example, because the MIC distribution of rpoB D435V (0.12 to
0.5 g/ml) overlapped the gWT distribution of rifabutin, the normal variation in MIC testing would result in a poor reproducibility of pDST for this mutation.
(C) WHO has only endorsed a single critical concentration for isoniazid, whereas CLSI has set an additional breakpoint that deﬁnes high-level resistance. Some
treatment guidelines recommend the treatment of low-level resistant strains with a high dose of isoniazid (18). All mutant isolates were found to be resistant
even at the second CLSI breakpoint, which was in accordance with our prediction based on WGS data (18). This would not have been apparent using the
GenoType MTBDRplus assay, given that it only interrogates inhA promoter mutations, which typically result in low MICs, although this did not affect our
interpretation of the assay, since we only relied on the WHO CCs (18).
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tible at 2.5 g/ml, and no MIC data were available for this isolate) (26). Two isolates had
a previously unknown deletion of the upstream and coding regions of eis, which
resulted in an invalid result with the MTBDRsl assay. The effect of this change on
kanamycin resistance remains to be determined.
No discrepancies were observed for amikacin and capreomycin (28).
Other antibiotics. No discrepancies were found for streptomycin and pyrazinamide
(29–33). For linezolid, isolate 9685-14 had a novel 23S mutation (rrl 906 g/a) that was
observed in a susceptible isolate.
For the remaining antibiotics, we found evidence of false-susceptible pDST results.
In the case of ethambutol, all 25 isolates were classiﬁed as gNWT but four tested
susceptible (34–36). Up to ﬁve isolates, as opposed to two just phenotypically con-
ﬁrmed isolates, might have been cycloserine resistant given that the recently proposed
tentative ECOFF of 20 g/ml is below the CC of 30 g/ml (37). Finally, up to six
additional isolates could have been resistant to para-aminosalicylic acid based on the
WGS data (see results in the supplemental material).
DISCUSSION
We investigated how different genotypic DST assays inﬂuence the design of stan-
dardized algorithm-derived M/XDR-TB regimens. As expected, the accuracy of predict-
ing resistance and, consequently, the ability to design appropriate treatment regimens
correlated with the proportion of the genome analyzed. Moreover, we demonstrated
that the pDST results were ﬂawed in some cases.
Although LPAs have been endorsed by the WHO for the rapid molecular prediction
of drug resistance of rifampin, isoniazid, ﬂuoroquinolones, and SLIDs, Xpert is the most
frequently used assay for initial routine molecular DST in many high-burden countries
FIG 4 MIC distributions for levoﬂoxacin and moxiﬂoxacin. The pooled MIC data identiﬁed potential breakpoint
artifacts for both agents. First, the CLSI and WHO critical concentrations for levoﬂoxacin were one dilution higher
than the tentative ECOFF deﬁned in this study (1.5 versus 0.75 g/ml) (11, 14). Second, the pooled data supported
the current CLSI critical concentration (0.25 g/ml) as the tentative ECOFF for moxiﬂoxacin rather than the value
set by WHO (0.5 g/ml), which is designed as a surrogate for testing resistance to oﬂoxacin and levoﬂoxacin (24).
Moreover, WHO has acknowledged that the critical concentration at 2 g/ml, which deﬁnes resistance to
moxiﬂoxacin, may be too high (24). Because two isolates with different genetic backgrounds shared the same gyrB
A504V mutations, which is typically a signal of positive selection, these isolates were categorized as unclear.
However, MIC testing revealed MICs that were equal to or below even the tentative ECOFFs for both ﬂuoroquino-
lones, which was in line with allelic exchange experiments (59).
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(6). Based on our results, it is a good test to rule in rifampin-resistant TB that can be
used as surrogate marker for M/XDR-TB depending on the geographical region. How-
ever, it is paramount that these results are complemented with additional DST, since
treatment regimens based only on an Xpert result would have led to the ineffective
administration of approximately half of the drugs in this cohort of patients who were
predominantly from eastern Europe. This will be different in other geographic settings,
where the extent of drug resistance beyond rifampin and isoniazid is lower (38, 39).
The prediction of resistance to ﬂuoroquinolones and SLIDs by LPAs was generally
accurate for patients in this cohort. However, this test was also insufﬁcient to construct
appropriate M/XDR-TB regimens compared with pDST, especially in patients with
XDR-TB. For example, almost all of the patients with M/XDR-TB from this cohort had
strains that were resistant to ethambutol and pyrazinamide, which are not covered by
the MTBDRsl 2.0. This was in line with results from a European study at 26 different
centers in high-intermediate- and low-TB-burden countries that reported resistance to
pyrazinamide and ethambutol in 59.7% and 59.3% of all patients with MDR-TB (94.4%
and 81.8% of patients with XDR-TB), respectively (38, 39).
The M/XDR-TB treatment regimens based on WGS showed the highest agreement
(93% [95% CI, 88 to 98%]) with those based on pDST. Unlike the other genotypic assays,
WGS did not miss any phenotypically conﬁrmed resistances but did predict resistance
in some phenotypically susceptible isolates. This was partly due to the fact that we
identiﬁed novel or poorly deﬁned mutations that we could not interpret with regard to
their impact on resistance development (e.g., mutations in rrl or gyrB; Table S2). Here,
we adopted a conservative approach and assumed that these mutations conferred
resistance, until disproved by another method, e.g., MIC determination of mutants
derived from allelic exchange experiments and sequential patient-derived isolates that
allow the interpretation of individual mutations and their effect on the drug resistance
level in a particular phylogenetic strain background.
In other cases, problems with pDST played a role. The false-susceptible pDST results
FIG 5 MIC distributions for kanamycin, amikacin, and capreomycin. The direct alteration of rrs, the shared target of kanamycin,
amikacin, and capreomycin, via the A1401G mutation is known to confer unequivocal cross-resistance to all three drugs, which was
in agreement with the pooled MIC data (60). In contrast, the current CCs for kanamycin were found to truncate the MIC distribution
for isolates with eis and whiB7mutations (27). This meant that isolates with a MIC of 2.5 g/ml were misclassiﬁed as susceptible despite
the fact that these included mutations had been shown to result in elevated MICs using allelic exchange experiments (i.e., eis37 g/t,
eis10 g/a, and whiB7116 a/g) (25, 26). In contrast, neither eis nor whiB7mutations had a signiﬁcant impact on the MICs of amikacin
or capreomycin (based on previous data, the fact that the tentative ECOFF for capreomycin for our study was below the critical
concentration was likely an artifact due to the small number of gWT isolates included in this study) (61).
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for ethambutol were likely due to the fact that some resistance mutations only result
in slight MIC increases, which means that it can be difﬁcult to distinguish the gWT
strains from gNWT strains using pDST, unless secondary mutations increase the MICs
even further (14, 40–42). The lack of reproducibility of pDST was also apparent for
isolate 3758-14, which initially tested susceptible to prothionamide but became resis-
tant upon retesting (Table S2).
Our results highlighted breakpoint artifacts (i.e., cases in which the current CCs were
likely set above the tentative ECOFFs) as a major cause for systematic errors. In the
absence of well-documented, high-quality evidence that isolates with elevated MICs
can be treated with the standard or an elevated dose, the CCs for these drugs should
be lowered to the tentative ECOFFs to avoid misdiagnosing isolates with elevated MICs
as susceptible (12, 13). One possibility to gather such evidence would be to conduct a
placebo-controlled study in which high-dose rifampin or rifabutin is used to treat
low-level rpoB resistance mutations as part of a backbone M/XDR-TB regimen (43).
Importantly, we raised the possibility that breakpoint artifacts exist for six drugs that
constitute the backbone of the treatment of drug-susceptible TB or MDR-TB (i.e.,
rifampin, levoﬂoxacin, moxiﬂoxacin, and kanamycin) in addition to less widely used
drugs (i.e., rifabutin and cycloserine). The impact of this phenomenon depends on the
geographic setting. For example, low-level resistance mutations in rpoB account for
more than 10% of rifampin resistance in Bangladesh but are less frequent in other
countries (44, 45). Problems related to kanamycin pDST likely are important in eastern
Europe, where eis mutations are widespread among the dominant MDR-TB clones
(46, 47).
This study was limited given that it was retrospective and only featured a small
number of MDR and XDR patients from a single center, although the comparison
between genotypic DST and pDST was strengthened by inclusion of MIC determina-
tions of fully susceptible isolates from Sweden (n  15). Our results did not provide
direct evidence that treatment regimens based on different genotypic DST methods
have an impact on clinical outcomes. Moreover, data from more laboratories including
both drug-resistant and drug-susceptible isolates are required to set ECOFFs with
conﬁdence (16, 48). Nevertheless, the fact that potential breakpoint artifacts were
found for so many key drugs underlines the urgent need for both CLSI and WHO to
reexamine their CCs, which were set largely based on expert opinion using evidence
that was not or was insufﬁciently documented, as opposed to modern and transparent
principles pioneered by the European Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) (6, 12, 16). Importantly, this should include clear recommendations about
how to proceed when discrepant results between genotypic assays and pDST are found
(49). Ideally, these recommendations should consider MICs as well as clinical outcome
data.
In conclusion, the strength of this study was that instead of merely calculating the
concordance of genotypic DST results with those of pDST, as is customary for these
assessments, we also compared the resulting regimens. In our view, this is more
clinically meaningful, as TB is never treated with a single drug (in effect, we assessed the
situation in settings that lack the laboratory infrastructure for pDST or, alternatively,
the period while pDST is being carried out, but these results are not yet available). This
is an important distinction, since the concordance of a genotypic DST assay with pDST
can be deceptively high (96% [95% CI, 80 to 100%] for Xpert in our case), yet more than
half of the drugs in the resulting regimens would still be prescribed inappropriately.
Therefore, Xpert and LPA results should only be used to rule in resistance to WHO
group A/B drugs and need to be complemented with further testing. WGS can provide
important additional information on resistance to WHO group C/D drugs but cannot
replace pDST completely either (e.g., pDST is still needed for novel mutations and to
detect resistance caused by known resistance mutations that occur at frequencies
below the detection limit of WGS [6]). Finally, the CCs need to be reevaluated to avoid
systematic false-susceptible pDST results for a variety of ﬁrst- and second-line drugs.
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MATERIALS AND METHODS
Study population. All patients (n 25) with a diagnosis of M/XDR-TB admitted to the Medical Clinic
of the Research Center Borstel (Germany) between March 2013 and March 2015 were included consec-
utively in the study.
Microbiology, pDST, and MIC testing. The primary detection, enrichment, DST, and MIC testing for
the Germany isolates were done under routine conditions at the German National Reference Laboratory
for Mycobacteria, Borstel. The following CCs, in micrograms per milliliter, were used for pDST with the
Bactec 960 MGIT system using a critical proportion of 1% for all drugs, with the exception of pyrazin-
amide, for which 10% was employed: rifampin (1.0), rifabutin (0.5), isoniazid (0.1), prothionamide (2.5),
oﬂoxacin (2.0), levoﬂoxacin (1.5), moxiﬂoxacin (0.5 and 2.0), kanamycin (2.5), amikacin (1.0), capreomycin
(2.5), para-aminosalicylic acid (4.0), streptomycin (1.0), ethambutol (5.0), pyrazinamide (100.0), and
linezolid (1.0) (11, 14). Cycloserine was tested using the proportion method on Löwenstein-Jensen
medium using a CC of 30 g/ml and a critical proportion of 1% (14).
The following concentrations, in micrograms per milliliter, were included for MGIT MIC testing for
clinical isolates: rifampin (0.12, 0.25, 0.5, 1.0, 4.0, and 20.0), rifabutin (0.06, 0.12, 0.25, 0.5, 2.0, and 10.0),
isoniazid (0.1, 0.4, 1.0, 3.0, and 10.0), prothionamide (0.62, 1.25, 2.5, 5.0, 10.0, and 25.0), levoﬂoxacin (0.18,
0.37, 0.75, and 1.5), moxiﬂoxacin (0.06, 0.12, 0.25, and 0.5), kanamycin (0.31, 0.62, 1.25, 2.5, 5.0, 12.5, and
25.0), amikacin (0.12, 0.25, 0.5, 1.0, 4.0, 20.0, and 40.0), capreomycin (0.31, 0.62, 1.25, 2.5, 5.0, 12.5, and
25.0), and para-aminosalicylic acid (0.5, 1.0, 2.0, and 4.0). The following concentrations ranges, in
micrograms per milliliter, were tested in 2-fold dilutions for the M. tuberculosis H37Rv ATCC 27294
reference strain: rifampin (0.06 to 0.5), rifabutin (0.06 to 0.5), isoniazid (0.006 to 0.05), prothionamide (0.31
to 2.5), levoﬂoxacin (0.09 to 1.5), moxiﬂoxacin (0.06 to 0.5), kanamycin (0.31 to 2.5), amikacin (0.12 to 1),
capreomycin (0.31 to 2.5), para-aminosalicylic acid (0.5 to 4), and linezolid (0.12 to 1).
Molecular DSTs. All baseline sputum specimens were analyzed with the Xpert assay according to the
recommendations of the manufacturer. Genomic DNA extracted with cetyltrimethylammonium bromide
from Löwenstein-Jensen cultures was used for the MTBDRplus 2.0 and MTBDRsl 2.0 LPAs as well as for
WGS using a modiﬁed Illumina NexteraXT protocol and the MiSeq or NextSeq sequencer (20, 50–52). The
detection of an inhA promoter variant with the MTBDRplus was used to infer prothionamide resistance
(18). The raw data (fastq ﬁles) were submitted to the European Nucleotide Archive (see Table S2 in the
supplemental material). Resulting reads were aligned to the M. tuberculosis H37Rv genome (GenBank
accession no. NC_000962.3) using BWA-MEM (53). The GATK software package was utilized for base
quality recalibration and alignment correction for possible PCR or insertion/deletion artifacts (54).
Polymorphisms with a minimum of 10 coverage and 75% variant frequency were extracted and
combined for all isolates using customized perl scripts. We focused our analysis on 33 resistance genes
(Table S6) for which known polymorphisms that do not correlate with resistance (i.e., phylogenetic
variants) were excluded (Table S7) (5, 55, 56).
WGS data were analyzed as follows (15). Isolates that did not have any mutations or only harbored
neutral polymorphisms in drug resistance genes (Table S7) were classiﬁed as genotypically wild type and
were assumed to be susceptible (gWT-S). Isolates with mutations known to result in MICs above the
current CC that deﬁnes resistance [i.e., MICs  CC(R)] were classiﬁed as genotypically non-wild type and
resistant (gNWT-R). Where two CCs have been set to deﬁne intermediate resistance (i.e., isolates that are
treatable with an elevated dose of the drug), isolates with mutations that result in MICs within this range
[i.e., CC(S)  MIC  CC(R)] were gNWT intermediate (gNWT-I). gNWT susceptible (gNWT-S) was used to
refer to isolates with mutations that confer elevated MICs below the lowest CC [i.e., ECOFF  MIC 
CC(S)]. Isolates with likely or known resistance mutations that do not necessarily result in MICs above the
CC(S/R) (i.e., in the case of ethambutol and kanamycin) or that confer MIC increases above the CC(S) but
not necessarily above the CC(R) were classiﬁed as simply gNWT. Mutations with no or insufﬁcient
evidence with regard to their effect on MICs were classiﬁed as unclear.
Algorithm-derived treatment regimens. We retrospectively designed treatment regimens based
on the results obtained from each DST method (pDST, Xpert, LPAs, and WGS) using current MDR-TB
treatment recommendations, as outlined in the supplemental material (3). To err on the side of caution,
unclear and gNWT mutations from WGS were considered to be resistant. The 367 initial pDST results
served as a reference standard for all comparisons (15 drugs for 25 patients with eight missing results,
which could not be conducted because of biosafety concerns).
Statistics. Concordance between each diagnostic test result with phenotypic DST was scored for
every individual on a scale from 0 to 1, with 0 representing no concordance and 1 perfect concordance
for each individual test result. The same approach was used to assess the overlap between the different
treatment regimens for each individual regimen. Differences in scores were evaluated using the
Mann-Whitney U test. The overlap between different diagnostic methods and the agreement between
the different treatment regimens were evaluated using the differences in proportions where each drug
from a given group was considered independently. Graphs were created and statistics calculated using
STATA version 14 (STATA Corp., Texas, USA) and Prism version 5 (GraphPad Software Inc., La Jolla,
California, USA). P values below 0.05 were considered signiﬁcant.
Determining tentative ECOFFs. We set tentative ECOFFs by visual inspection for a variety of
antibiotics (statistical methods could not be used given the MIC data did not meet the minimum
requirements speciﬁed by EUCAST to set ECOFFs [48]). For this purpose, we pooled the MICs from the
German patient cohort with MICs from a Swedish collection (see the supplemental material) and the
literature wherever the individual concentrations and concentration ranges were sufﬁciently similar (17,
19, 27, 57, 58). As shown in Table S8, we had to truncate some of the distributions for this purpose. For
Kambli et al. we excluded one isolate for which the genetic basis of the elevated MICs was not clear (27).
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We did not display the MICs for gyrB mutations from Nosova et al. given the mutations differed from the
gyrB A504V mutation observed in our study (57). We only included MIC data for rpoB mutations from
Berrada et al. that also occurred in the German isolates (17).
Ethics. The ethics committee of the University of Lübeck, Germany, approved the study (15-195A).
Approval for whole-genome sequencing and analysis of the isolates from Sweden was granted by the UK
National Research Ethics Service (12/EE/0439) and the Cambridge University Hospitals NHS Foundation
Trust R&D Department (A092685).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.01550-17.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.5 MB.
SUPPLEMENTAL FILE 2, XLSX ﬁle, 0.1 MB.
SUPPLEMENTAL FILE 3, XLSX ﬁle, 0.1 MB.
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